This approval is a key step in the development of the company’s digital therapy platform iSTRYM
VANCOUVER, BC, March 9, 2021 / PRNewswire / – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MENTION” or the “Company”), a leader in proprietary advanced psychedelic therapy technology, is pleased to announce that it has received unconditional ethical approval from Veritas IRB for its Integration Protocol research study. This study will serve to inform the development of the company’s digital therapy platform, iSTRYM, and how it is designed to best serve therapists, patients and the entire psychedelic industry.
“This is a monumental step for MINDCURE and our digital therapeutic strategy”, mentionned Kelsey ramsden, President and CEO, MINDCURE. “As we build iSTRYM to become the largest repository of data for psychedelic experiences, we ensure that its development is based on research evidence and a deep understanding of the systems and protocols provided during psychedelic therapy. This ethical approval from Veritas signifies both validation of this study, as well as the importance we place on building trust and integrity with therapists and patients. “
“The impact of psychedelics is so vast that even subtle variations in integration approaches can create a dramatic impact on a client’s trajectory,” said Dr. Mitch earleywine, professor of psychology at the University of Albany, State University of New York and sub-investigator on this study for MINDCURE. “This work is intended to discover important contributors to the best results of psychedelic-assisted therapy. Formal research on integration is in its infancy, and traditional approaches did not last for centuries by accident. An intriguing experience is of course great, but changing someone’s overall perspective can create gains that will continue to improve quality of life year after year. this study published in Journal of Psychedelic Studies.1
Veritas Independent Research Board (IRB) is the first and only central IRB accredited and owned by Canadians. Recognized as a leader in research ethics, Veritas IRB has long been the research ethics board of choice for Canadian government departments, teaching hospitals, regional hospitals, private research centers and non-governmental organizations. government agencies conducting human research. Since its creation in 1996, its Board of Directors has been committed to ensuring that its processes respect the rights of participants and that its services are provided according to the highest standards of ethics and clinical practice.2
Earleywine, M., & De Leo, J. (2020). Psychedelic Psychotherapy For Depression: How Urgent Is The Need? How could we do it ?. Journal of Psychedelic Studies.
About Mind Cure Health (MINDCURE) Inc.
MINDCURE exists in response to the current mental health crisis and urgent calls for effective treatment. MINDCURE believes in the need to reinvent the model of mental health care for patients and practitioners to enable psychedelics to progress towards common and accepted care.
MINDCURE focuses on identifying and developing pathways and products that alleviate suffering, increase productivity, and improve mental health. MINDCURE is interested in exploring various therapeutic areas beyond psychiatry, including digital therapy, neuro-supports, and psychedelics, all for improving mental health.
On behalf of the board of directors
Kelsey ramsden, President and CEO
Certain statements contained in this press release may constitute “forward-looking information” within the meaning of applicable securities laws (also called forward-looking statements). Forward-looking information involves risks, uncertainties and other known and unknown factors, and may cause actual results, performance or achievements or industry results to be materially different from future results, performance or achievements or results of industry expressed or implied by such research information. Forward-looking information can generally be identified by the use of terms and phrases such as “anticipate”, “believe”, “might”, “estimate”, “expect”, “feel”, “have the intention “,” could “,” plan “,” foresee “,” project “,” subject to “,” will “,” would “, and similar terms and expressions, including references to assumptions. Some of the specific forward-looking information contained in this press release include, without limitation, statements regarding: MINDCURE’s Psychedelic Integration Protocol research study informing the Company’s development of iSTRYM; iSTRYM potentially becoming the largest repository of data on psychedelic experiences; this study uncovering important contributors to the best results of assisted psychedelic therapy; and that altering someone’s experience with psychedelics can create gains that will add quality of life year after year.
Forward-looking information is based on a number of key expectations and assumptions made by MINDCURE, including, but not limited to: the impact of the COVID-19 pandemic on the Canadian economy and MINDCURE’s operations , as well as the extent and duration of this impact; no changes in laws or regulations that adversely affect MINDCURE’s activities; there will be a demand for MINDCURE products in the future; no unforeseen expenses or costs arise; MINDCURE can continue to identify products that make them ideal candidates for providing mental health treatment solutions; whereas the functional mushroom industry will continue to grow; this research study on the integration protocol will inform MINDCURE for the development of its iSTRYM platform; and MINDCURE will be able to operate as planned. Although the forward-looking information contained in this press release is based on what MINDCURE considers reasonable assumptions, it cannot assure investors that actual results will be consistent with such information.
Forward-looking information is provided for the purpose of presenting information about management’s current expectations and plans for the future, and readers are cautioned that such statements may not be appropriate for other purposes. Forward-looking information involves significant risks and uncertainties and should not be interpreted as a guarantee of future performance or results, as actual results may differ materially from those expressed or implied in such forward-looking information. These risks and uncertainties include, among others, risks related to: the impacts of the COVID-19 pandemic on the Canadian economy, the industry of MINDCURE and the operations of MINDCURE, which may have a negative impact and may continue to be negatively impact MINDCURE and may have a material adverse impact on MINDCURE’s investments, results of operations, financial condition and MINDCURE’s ability to obtain additional equity or debt financing, and to meet its obligations financial; general economic conditions; potential for future growth; competition for investments in mental health and well-being; this research study on the integration protocol may not inform MINDCURE for the development of its iSTRYM platform; and changes in laws or regulations. Management believes that the expectations reflected in the forward-looking information contained in this document are based on reasonable assumptions and information currently available; however, management cannot guarantee that actual results will be consistent with this forward-looking information. Additional information on risk factors that could affect MINDCURE can be found under “Risk Factors” in MINDCURE’s final prospectus which is available on SEDAR at www.sedar.com.
The forward-looking information contained in this document is expressly qualified in its entirety by this cautionary statement. Forward-looking information reflects the current beliefs of management and is based on information currently available to MINDCURE. Forward-looking information is set out as of the date of this press release and MINDCURE assumes no obligation to update or revise such information to reflect new events or circumstances, except as required by applicable law.
The CSE has neither approved nor disapproved the contents of this press release and the CSE accepts no responsibility for the adequacy or accuracy of this press release.
SOURCE Mind Cure Health Inc.